💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pantoprazole

CHEMBL1502 Phase 4 Aprobado Small molecule
Half-Life
1 hour
Bioavailability
—
Protein Binding
—
Molecular Weight
383.4 g/mol
LogP
2.4
Phase
4

This proton pump inhibitor reduces stomach acid production to treat acid reflux, ulcers, and esophageal damage.

Peso molecular

383,3710 g/mol

LogP

2,40

TPSA

106,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Dermatitis atópica Diabetes tipo 2 Dolor crónico Enfermedad del hígado graso no alcohólico Enfermedad por reflujo gastroesofágico Esclerosis múltiple Esquizofrenia Fibrilación auricular Hipertensión Insuficiencia cardíaca Manejo del dolor Migraña Obesidad Oncología

Clases de fármacos

A — A - Aparato digestivo y metabolismo

Mecanismo de acción

Proton pump inhibitor.

Pharmacokinetics (PK)

Half-Life 1 hour

Pharmacodynamics (PD)

Mecanismo

Proton pump inhibitor.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC

                

                

                
                

                    
InChI

                    
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H15F2N3O4S

                    

                    
                    

                        
HBD / HBA

                        
1 / 9

                    

                    
                    

                        
Enlaces Rotables

                        
7

                    

                    
                    
                    

                        
Átomos Pesados

                        
26

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ATP4A (Bomba de protones (H+/K+-ATPasa))
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Pantoprazole + Clopidogrel
                            
                        

                        
                        
Pantoprazole has minimal CYP2C19 inhibitory activity compared with omeprazole, making it the preferred PPI choice in patients on clopidogrel.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Pantoprazole + Levothyroxine
                            
                        

                        
                        
Like all PPIs, pantoprazole reduces gastric acid and impairs levothyroxine tablet dissolution, leading to decreased T4 absorption and potentially under-treated hypothyroidism.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
This proton pump inhibitor reduces stomach acid production to treat acid reflux, ulcers, and esophageal damage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Proton pump inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Pantoprazole: Half-life: 1 hour.

                        

                    

                    

                    

                        
                        

                            
Yes, Pantoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                        
                            Insulin Glargine
                            Protein
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1502.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4679.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.